Cryonics Revival Scenarios & Potential Roadmaps & Hypotheses

Pharmaceutical companies fund most clinical research, shaping medical science to favor profit over patients. How does industry influence distorted outcomes and what can be done to ensure independent, transparent research?

Whether facing a global pandemic, navigating chronic illness or responding to environmental threats, society looks to medical science to heal, protect and advance our collective well-being.

But beneath the surface of peer-reviewed journals and cutting-edge discoveries lies a troubling reality: the pharmaceutical industry. The industry is worth over $1.6 trillion globally, according to Statista, and has an outsized influence on the direction, design and outcomes of scientific research.

By funding a significant portion of clinical studies, pharmaceutical companies can shape not only which questions get asked but also how results are interpreted and shared.

This raises a pressing question where it must be established if the industry is driven by profit and who is science really serving? Is it the patients or shareholders?

Research for Sale

More than half of all clinical trials are now funded by pharmaceutical companies, according to JAMA network. At first glance, this might seem like a win-win situation. Private funding supports innovation, and the public reaps the medical benefits, however, when profit becomes the driving force, priorities shift.

Pharmaceutical companies are far more likely to fund studies for drugs that promise high financial returns, even when cheaper, more effective alternatives already exist.

Research into rare diseases, non-patentable treatments or preventive care are areas that could profoundly benefit public health and remain underfunded. The reason is simple. There is no money to cure what affects only a few or to prevent disease when treatment is more profitable.

https://thehilltoponline.com/2025/03/31/medical-science-should-serve-people-not-pharmaceuticals/